Latest news and press releases about Dare Bioscience, Inc. (DARE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Price
| Price | $0.75 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -19.54 |
| EV / EBITDA | -0.53 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -748.08% |
| Return on Invested Capital | -179.10% |
| Return on Assets | -49.12% |
| Gross Margin | -89.45% |
| Operating Margin | -813.38% |
| Net Margin | -804.37% |
Related companies: ADTX · AIMD · ANL · ASBP · ATHA · CTXR · FBLG
Explore sector: Healthcare · Biotechnology
More sections of DARE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks